How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/opiate-induced-respiratory-depression.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Opiate-Induced Respiratory Depression — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Opiate-Induced Respiratory Depression (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Opiate-Induced Respiratory Depression, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	Line of therapy	First approval
Revex	NALMEFENE	Hikma	Opioid Antagonist	Kappa-type opioid receptor		1995-01-01
Narcan	NALOXONE	Adapt	Opioid Antagonist	Mu-type opioid receptor		1971-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Adapt · 1 drug in Opiate-Induced Respiratory Depression
Hikma · 1 drug in Opiate-Induced Respiratory Depression

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Opiate-Induced Respiratory Depression:

Cite this brief

Drug Landscape (2026). Opiate-Induced Respiratory Depression — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/opiate-induced-respiratory-depression. Accessed 2026-06-10.

Opiate-Induced Respiratory Depression full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing